By Meghan McCarthy
In a recently published manuscript, researchers at the Penn Frontotemporal Degeneration (FTD) Center found that African American patients and those of low socioeconomic status are significantly less likely to access neurogenetic evaluation compared to White patients.
These findings exemplify systemic barriers and health inequities and have a direct impact on the equitable inclusion of marginalized groups in clinical trials related to Alzheimer’s disease and related dementias (ADRDs).